Next-Generation Biomanufacturing Market - Global Forecast 2025-2032

Next-generation biomanufacturing is reshaping the global life sciences sector by empowering organizations to achieve operational efficiency, faster production cycles, and increased flexibility. As innovation and technological advancements continue to drive change, senior decision-makers face the challenge—and opportunity—of adapting strategies to capitalize on market shifts.

Market Snapshot: Growth Trends in the Next-Generation Biomanufacturing Market

The global next-generation biomanufacturing market is experiencing sustained growth, with a market value of USD 20.69 billion in 2024 and a projection to reach USD 22.66 billion in 2025. The sector's compound annual growth rate (CAGR) of 9.38% will help propel it to USD 42.43 billion by 2032. Growth is largely fueled by continuous improvements in bioproduction technology, an expanding demand for targeted healthcare outputs, and robust adoption of automation across manufacturing operations. Investment in scalable, flexible manufacturing infrastructure is enabling companies to address emerging market demands, while competition drives firms to deliver advanced therapies efficiently across a dynamic and evolving landscape.

Scope & Segmentation: Comprehensive Industry Coverage

• Product Types: Cell and gene therapies (including CAR-T and gene editing applications), enzyme products for clinical and industrial purposes, monoclonal antibodies, recombinant proteins (such as hormones and cytokines), and a range of vaccine formats including mRNA, subunit, and viral vector platforms.
• Technologies: Adoption of cell-free expression systems, continuous bioprocessing techniques, advanced chromatography, real-time process monitoring, modular facility layouts, plus single-use equipment for production adaptability and efficiency.
• Process Stages: Full life-cycle coverage, from upstream bioreactor management and cultivation to downstream purification, filtration, formulation, filling, lyophilization, and packaging phases.
• End Users: Academic researchers, biotechnology and pharmaceutical companies, and contract manufacturers; each group drives innovation, facilitates technology transfer, and contributes unique expertise to the sector.
• Operation Scales: Applicability spans pilot programs, clinical production, and commercial manufacturing, meeting the needs of both early development and product launch phases.
• Cell Lines: Deployment of CHO (DG44, K1), E. coli (BL21, K12), and yeast strains (Pichia pastoris, Saccharomyces cerevisiae) to support a wide spectrum of production innovations.
• Process Modes: Flexible use of batch, fed-batch, continuous, and perfusion manufacturing to optimize productivity, responsiveness, and resource use based on commercial and clinical targets.
• Geographical Regions: Analysis covers the Americas (U.S., Canada, Latin America), Europe, Middle East, Africa, and Asia-Pacific; regional assessment highlights China, India, Japan, Australia, South Korea, and Southeast Asia for their diverse growth patterns and innovation adoption.
• Company Coverage: Strategies and competitive dynamics examined across key industry players such as Novozymes A/S, Koninklijke DSM N.V., Evonik Industries AG, Ginkgo Bioworks Holdings, Amyris, Codexis, Zymergen, Genomatica, Evolva Holding, and LanzaTech.

Key Takeaways: Strategic Insights for Executives in Next-Generation Biomanufacturing

• Continuous bioprocessing drives manufacturing consistency and simplifies technology transfer across geographic locations, helping companies sustain quality standards globally.
• Modular manufacturing plants combined with single-use systems make it possible to scale production rapidly, ensuring capacity aligns with shifts in therapeutic demand and regional healthcare trends.
• Advanced analytics and digital twin technology facilitate asset optimization and predictive maintenance, enabling real-time problem detection and resolution in complex production environments.
• Collaboration across regions, underpinned by investment and innovation in both established and high-growth markets, fosters new public-private initiatives and supports sector-wide advancement.
• Strategic alliances with technology suppliers and academic partners accelerate market entry for new biologics, while reducing time-to-market risks and promoting efficient knowledge transfer.
• The adoption of emerging biomanufacturing methods, such as cell-free synthesis and viral vector targeting, provides agility for navigating shifting clinical and regulatory requirements with improved readiness.

Tariff Impact: Navigating U.S. Policy Shifts in Biomanufacturing

Anticipated U.S. tariffs for 2025 will increase costs associated with sourcing raw materials and specialized biomanufacturing equipment. In response, organizations are evolving procurement strategies and realigning inventory practices to safeguard supply chain stability. The shifting policy landscape is stimulating growth in domestic modular production capacity and elevating the role of scenario-based risk management. Robust engagement with regulatory bodies and industry consortia is key for adapting, as companies emphasize agile models to maintain competitiveness and compliance in the U.S. market environment.

Methodology & Data Sources: Rigorous and Actionable Intelligence for Stakeholders

This analysis uses data from direct interviews with senior executives at biopharmaceutical and contract manufacturing organizations. All findings are independently cross-validated using peer-reviewed research and verified regulatory filings, and the data undergo strict quality controls to support leadership decision-making.

Why This Report Matters

• Presents segment-specific insights across products, geographies, and technologies, providing senior leaders with clear guidance for strategic investment and planning.
• Offers tools to anticipate and address supply chain challenges in the face of regulatory changes, using reliable and actionable intelligence.
• Enables more confident partnership and resource decisions, clarifying the trends driving transformation in global biomanufacturing.

Conclusion

This report delivers vital intelligence for executives focused on building resilient, future-ready business models. Leverage these findings to anticipate changes and refine your biomanufacturing strategy.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.